Journal of General Surgery for Clinicians ›› 2023, Vol. 11 ›› Issue (4): 31-.

Previous Articles     Next Articles

The clinical application of ertapenem in community-acquired intraabdominal infection and perioperative period

  

  1. 1. Pharmacy Department of Qingdao Municipal Hospital, Shandong Qingdao 266071, China; 2. Pharmacy Department of Rizhao Central Hospital, Shandong Rizhao 276800, China; 3. Clinical Pharmacy Institute of Jining First People's Hospital, Shandong Jining 272000, China
  • Online:2023-10-01 Published:2023-12-26

Abstract:

Abdominal infection is one of the common acute and critical diseases in surgery, with a high incidence rate and mortality. In addition to symptomatic support treatment such as surgery and fluid resuscitation, anti-infection treatment is an important treatment method. As a carbapenem drug, although ertapenem has been recommended as a first-line treatment drug for community abdominal infection by major guidelines and consensus at home and abroad, However, when conducting empirical anti infection treatment in clinical practice, it is more inclined to choose other carbapenems, as well as third-generation cephalosporins and/or nitroimidazoles, fluoroquinolones and other antibacterial drugs, and less to choose ertapenem for treatment. This article aims to review the effects of ertapenem on bacterial resistance, the advantages of its safety, effectiveness, and economy in

treating community abdominal infections, as well as the impact of perioperative prophylactic use on the incidence of postoperative infections, in order to provide reference for its widespread clinical application.

Key words: Ertapenem, Abdominal infection, Perioperative period, Preventive medication